KR20230107628A - Wnt 수용체 ryk에 대한 항체 변이체 - Google Patents

Wnt 수용체 ryk에 대한 항체 변이체 Download PDF

Info

Publication number
KR20230107628A
KR20230107628A KR1020237019599A KR20237019599A KR20230107628A KR 20230107628 A KR20230107628 A KR 20230107628A KR 1020237019599 A KR1020237019599 A KR 1020237019599A KR 20237019599 A KR20237019599 A KR 20237019599A KR 20230107628 A KR20230107628 A KR 20230107628A
Authority
KR
South Korea
Prior art keywords
antibody
seq
ryk
acid sequence
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237019599A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 엔. 하우저
테일러 엘. 캠퍼트
미아오 선
Original Assignee
버사퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 버사퓨틱스 인코포레이티드 filed Critical 버사퓨틱스 인코포레이티드
Publication of KR20230107628A publication Critical patent/KR20230107628A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • G01N33/57484—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020237019599A 2020-11-11 2021-11-08 Wnt 수용체 ryk에 대한 항체 변이체 Pending KR20230107628A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063112616P 2020-11-11 2020-11-11
US63/112,616 2020-11-11
PCT/US2021/058491 WO2022103705A1 (en) 2020-11-11 2021-11-08 Antibody variants against wnt receptor ryk

Publications (1)

Publication Number Publication Date
KR20230107628A true KR20230107628A (ko) 2023-07-17

Family

ID=81601681

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237019599A Pending KR20230107628A (ko) 2020-11-11 2021-11-08 Wnt 수용체 ryk에 대한 항체 변이체

Country Status (9)

Country Link
US (1) US20230416375A1 (https=)
EP (1) EP4244259A4 (https=)
JP (1) JP2023552919A (https=)
KR (1) KR20230107628A (https=)
CN (1) CN117295767A (https=)
AU (1) AU2021380681A1 (https=)
CA (1) CA3201419A1 (https=)
TW (1) TW202233683A (https=)
WO (1) WO2022103705A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172733A1 (en) 2016-03-28 2017-10-05 The Regents Of The University Of California Anti-ryk antibodies and methods of using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100522242C (zh) * 2001-02-19 2009-08-05 默克专利有限公司 具有降低的免疫原性的人工蛋白质
US8236307B2 (en) * 2007-08-03 2012-08-07 Genentech, Inc. Humanized anti-FGF19 antagonists and methods using same
EP3533803B1 (en) * 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
EP3828205A1 (en) * 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
US20130309223A1 (en) * 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
US9862776B2 (en) * 2013-04-03 2018-01-09 Peter Maccallum Cancer Institute Antibodies against human RYK and uses therefor
MA41480A (fr) * 2014-10-17 2017-12-19 Glenmark Pharmaceuticals Sa Anticorps qui se lient au ccr6 et leurs utilisations
DK3303396T5 (da) * 2015-05-29 2024-10-07 Bristol Myers Squibb Co Antistoffer mod ox40 og anvendelser deraf
WO2017172733A1 (en) * 2016-03-28 2017-10-05 The Regents Of The University Of California Anti-ryk antibodies and methods of using the same
AU2018224094B2 (en) * 2017-02-24 2025-04-17 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
TWI788340B (zh) * 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
GB201707561D0 (en) * 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies

Also Published As

Publication number Publication date
TW202233683A (zh) 2022-09-01
AU2021380681A1 (en) 2023-06-15
US20230416375A1 (en) 2023-12-28
EP4244259A1 (en) 2023-09-20
CA3201419A1 (en) 2022-05-19
JP2023552919A (ja) 2023-12-19
CN117295767A (zh) 2023-12-26
AU2021380681A9 (en) 2024-02-08
WO2022103705A1 (en) 2022-05-19
EP4244259A4 (en) 2025-01-15

Similar Documents

Publication Publication Date Title
ES2363622T3 (es) Moléculas de enlace de lingo y el uso farmacéutico de estas.
TWI770020B (zh) 人類化抗pacap 抗體及其用途
TWI729992B (zh) 用於治療共核蛋白病的藥劑、用途及方法
JP2024023445A (ja) 癌の成長を抑制する結合分子
JP6352812B6 (ja) 抗ｃｘｃｒ３抗体
JP5719596B2 (ja) 抗体及びその誘導体
BR112020025502A2 (pt) Anticorpos il-11ra
JP2018516361A (ja) 羞明を処置、予防、または阻害するための抗ｐａｃａｐ抗体及びそれらの抗原結合性断片の使用
KR20210142638A (ko) Cd3 항원 결합 단편 및 이의 응용
CN114133450B (zh) 抗-Rho GTPase的构象单域抗体及其用途
CN112566940A (zh) 多特异性wnt替代分子和其用途
CN107074937A (zh) 人源抗亨廷顿蛋白（htt）抗体及其用途
CA2960466A1 (en) Cancer cell-specific antibody, anticancer drug and cancer testing method
JP2018516549A (ja) 結合ポリペプチドを含む細菌を特定する方法
CN114641310A (zh) 治疗癌症和其他疾病的靶向α3β1整合素
TW202000232A (zh) 用以治療或預防異位性骨化之醫藥組成物
KR20230107628A (ko) Wnt 수용체 ryk에 대한 항체 변이체
JP2013542720A (ja) 抗エフリン−ｂ２抗体およびその使用
TW202337906A (zh) 抗ｐｉｌｒａ抗體、其用途以及相關方法及試劑
KR20230079074A (ko) 면역글로불린 ｅ 항체 조성물 및 사용 방법
US20240317867A1 (en) Igfr-like 2 receptor and uses thereof
HK40115111A (zh) 抗pilra抗体、其用途以及相关方法和试剂
TW202515915A (zh) 抗ｐｉｌｒａ抗體、其用途以及相關方法及試劑
WO2026082710A1 (en) Small molecule-inducible recombinant receptors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000